Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05984927 · ClinicalTrials.gov registry record · Phase 1
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
A Phase 1 study of Age-related Macular Degeneration, sponsored by Elisigen.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 5
- Study locations
NCT05984927 is a Phase 1 study of Age-related Macular Degeneration that is active but no longer recruiting, run by Elisigen. The registered enrollment target is 20 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT05984927, a Phase 1 study of Age-related Macular Degeneration, is active but no longer recruiting, sponsored by Elisigen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related macular degeneration (wAMD).
Conditions Studied
Interventions
- GENETIC NG101 AAV gene therapy
Study Locations (5)
Ontario
- Sunnybrook Ophthalmology and Vision Services - Toronto
- Vitreous Retina Macula Specialists of Toronto - Toronto
Ohio
- Cincinnati Eye Institute - Cincinnati
Texas
- Retina Consultants of Texas - Bellaire
British Columbia
- Vancouver Coastal Health Research Institute - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-09-08 |
| Est. Completion | 2030-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05984927
The ClinicalTrials.gov registry entry for NCT05984927 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (99% lower). The listed sponsor is Elisigen, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which NG101 AAV gene therapy is the first listed.
NCT05984927 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Ontario, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT05984927 about?
NCT05984927 is a clinical study titled "NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration". This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related macular degeneration (wAMD).
What is the current status of trial NCT05984927?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2023-09-08. Estimated completion is 2030-01.
What conditions does trial NCT05984927 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT05984927?
The interventions under investigation include: NG101 AAV gene therapy (GENETIC).
Who is sponsoring clinical trial NCT05984927?
This trial is sponsored by Elisigen, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05984927 being conducted?
This trial has 5 study locations across Ohio, Texas, British Columbia, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
-
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
RECRUITING · Phase 1
-
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
RECRUITING · Phase 1
-
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RECRUITING · Phase 1
-
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
RECRUITING · Phase 1
-
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.